Therapy-related myeloid leukemias (t-MLs) occur in as many as 5% to 10% of patients who are otherwise cured of a primary neoplasm with aggressive multimodal regimens. Many patients with t-MLs or therapy-related myelodysplastic syndrome (t-MDS) have previously received chemotherapeutic agents that
No takes yet. Share an insight, caveat, or question.
Geiger et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: